{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:51Z","timestamp":1794047451802,"version":"4.8.0"},"reference-count":38,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Over the past two decades, there have been significant advances in the treatment of multiple myeloma which has led to an improvement in overall survival.1,2 However, a notable proportion of patients continue to experience early mortality (EM), defined as 2 years from the time of diagnosis. This raises the possibility that improvements in myeloma survival have not extended equally to all groups. Using the latest data drawn from the Surveillance Epidemiology and End Results database of patients in the United States spanning 2000-2019, we study impact of important sociodemographic factors on EM. Through regression modeling, we demonstrate that patients diagnosed from 2000-2005, of older age, male sex, and of certain racial minority status (non-Hispanic Black and Hispanic) have higher odds of EM. Of these factors, minority status contributed to worse 2-year overall survival as well. We evaluate whether income, as a surrogate to access to care, could potentially explain this finding, but find that race has a distinct relationship with EM that is not modified by income. This is further reinforced by subgroup analysis. After characterizing groups vulnerable to EM, we examine reasons for these disparities and potential avenues to address them.<\/jats:p>","DOI":"10.3324\/haematol.2023.283304","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T03:48:04Z","timestamp":1698292084000},"page":"1480-1486","source":"Crossref","is-referenced-by-count":3,"title":["Impact of race and ethnicity on early mortality in multiple myeloma: a SEER analysis"],"prefix":"10.3324","volume":"109","author":[{"given":"John X.","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Shastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Alejandro","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Mantzaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Kornblum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urvi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Janakiram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira","family":"Gritsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mendel","family":"Goldfinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"60649","doi-asserted-by":"crossref","unstructured":"Legarda MA, Cejalvo MJ, de la Rubia J. Recent advances in the treatment of patients with multiple myeloma. Cancers (Basel). 2020; 12(12):3576.","DOI":"10.3390\/cancers12123576"},{"key":"60650","doi-asserted-by":"crossref","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008; 111(5):2516-2520.","DOI":"10.1182\/blood-2007-10-116129"},{"key":"60651","doi-asserted-by":"crossref","unstructured":"Hahn A, Giri S, Yaghmour G, Martin MG. Early mortality in acute myeloid leukemia. Leuk Res. 2015; 39(5):505-509.","DOI":"10.1016\/j.leukres.2015.02.003"},{"key":"60652","doi-asserted-by":"crossref","unstructured":"Reville PK, Nogueras Gonz\u00e1lez GM, Ravandi F. Predictors of early mortality, response, and survival in newly diagnosed acute myeloid leukemia (AML) using a contemporary academic cohort. Blood. 2020; 136(Suppl 1):44-45.","DOI":"10.1182\/blood-2020-141837"},{"key":"60653","doi-asserted-by":"crossref","unstructured":"Kim K, Jorge VM, Tiu A. Early mortality after diagnosis of diffuse large B-cell lymphoma : a retrospective, single urban-community hospital study. Blood. 2019; 134(Suppl 1):5335.","DOI":"10.1182\/blood-2019-132126"},{"key":"60654","doi-asserted-by":"crossref","unstructured":"Maddox JM. Predicting Early mortality in diffuse large B-cell non-Hodgkin lymphoma. Blood. 2016; 128(22):5411.","DOI":"10.1182\/blood.V128.22.5411.5411"},{"key":"60655","doi-asserted-by":"crossref","unstructured":"Joshua DE, Bryant C, Dix C, Gibson J, Ho J. Biology and therapy of multiple myeloma. Med J Aust. 2019; 210(8):375-380.","DOI":"10.5694\/mja2.50129"},{"key":"60656","doi-asserted-by":"crossref","unstructured":"Shah UA, Mailankody S. Emerging immunotherapies in multiple myeloma. BMJ. 2020; 370:m3176.","DOI":"10.1136\/bmj.m3176"},{"key":"60657","doi-asserted-by":"crossref","unstructured":"Perrot A, Corre J, Avet-Loiseau H. Risk stratification and targets in multiple myeloma: from genomics to the bedside. Am Soc Clin Oncol Educ Book. 2018; 38:675-680.","DOI":"10.1200\/EDBK_200879"},{"key":"60658","doi-asserted-by":"crossref","unstructured":"Hsu P, Lin TW, Gau JP. Risk of early mortality in patients with newly diagnosed multiple myeloma. Medicine. 2015; 94(50):e2305.","DOI":"10.1097\/MD.0000000000002305"},{"key":"60659","doi-asserted-by":"crossref","unstructured":"Greipp PR, Miguel JS, Durie BGM. International Staging System for multiple myeloma. J Clin Oncol. 2005; 23(15):3412-3420.","DOI":"10.1200\/JCO.2005.04.242"},{"key":"60660","doi-asserted-by":"crossref","unstructured":"McQuilten Z, Wellard C, Moore E. Predictors of early mortality in multiple myeloma: results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). Br J Haematol. 2022; 198(5):830-837.","DOI":"10.1111\/bjh.18324"},{"key":"60661","doi-asserted-by":"crossref","unstructured":"Charli\u0144ski G, Tyczy\u0144ska A, Ma\u0142ecki B. Risk factors and causes of early mortality in patients with newly diagnosed multiple myeloma in a \u201creal-world\u201d study: experiences of the Polish Myeloma Group. Pol Arch Intern Med. 2021; 131(6):527-534.","DOI":"10.20452\/pamw.15980"},{"key":"60662","doi-asserted-by":"crossref","unstructured":"Rusli E, Diao L, Liu C. Racial differences in multiple myeloma survival and treatment using pooled clinical trial and real-world electronic medical record data. Blood. 2020; 136(Suppl 1):9.","DOI":"10.1182\/blood-2020-142960"},{"key":"60663","doi-asserted-by":"crossref","unstructured":"Costa LJ, Brill IK, Omel J, Godby K, Kumar SK, Brown EE. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv. 2017; 1(4):282-287.","DOI":"10.1182\/bloodadvances.2016002493"},{"key":"60664","doi-asserted-by":"crossref","unstructured":"Marinac CR, Ghobrial IM, Birmann BM, Soiffer J, Rebbeck TR. Dissecting racial disparities in multiple myeloma. Blood Cancer J. 2020; 10(2):1-8.","DOI":"10.1038\/s41408-020-0284-7"},{"key":"60665","doi-asserted-by":"crossref","unstructured":"Pulte ED, Nie L, Gormley N. Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications. Blood Adv. 2018; 2(2):116-119.","DOI":"10.1182\/bloodadvances.2017010512"},{"key":"60666","doi-asserted-by":"crossref","unstructured":"Pulte D, Redaniel MT, Brenner H, Jeffreys M. Changes in survival by ethnicity of patients with cancer between 1992-1996 and 2002-2006: is the discrepancy decreasing?. Ann Oncol. 2012; 23(9):2428-2434.","DOI":"10.1093\/annonc\/mds023"},{"key":"60667","doi-asserted-by":"crossref","unstructured":"Ailawadhi S, Aldoss IT, Yang D. Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol. 2012; 158(1):91-98.","DOI":"10.1111\/j.1365-2141.2012.09124.x"},{"key":"60668","doi-asserted-by":"crossref","unstructured":"Watson EK, Rose PW, Neal RD. Personalised cancer follow-up: risk stratification, needs assessment or both?. Br J Cancer. 2012; 106(1):1-5.","DOI":"10.1038\/bjc.2011.535"},{"key":"60669","doi-asserted-by":"crossref","unstructured":"Dharmarajan KV, Presley CJ, Wyld L. Care disparities across the health care continuum for older adults: lessons from multidisciplinary perspectives. Am Soc Clin Oncol Educ Book. 2021; 41:1-10.","DOI":"10.1200\/EDBK_319841"},{"key":"60670","doi-asserted-by":"crossref","unstructured":"Goede V. Frailty and cancer: current perspectives on assessment and monitoring. Clin Interv Aging. 2023; 18:505-521.","DOI":"10.2147\/CIA.S365494"},{"key":"60671","doi-asserted-by":"crossref","unstructured":"Derhovanessian E, Solana R, Larbi A, Pawelec G. Immunity, ageing and cancer. Immun Ageing. 2008; 5(1):11.","DOI":"10.1186\/1742-4933-5-11"},{"key":"60672","doi-asserted-by":"crossref","unstructured":"Derman BA, Langerman SS, Maric M, Jakubowiak A, Zhang W, Chiu BCH. Sex differences in outcomes in multiple myeloma. Br J Haematol. 2021; 192(3):e66-e69.","DOI":"10.1111\/bjh.17237"},{"key":"60673","doi-asserted-by":"crossref","unstructured":"Kazandjian D, Landgren O. A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival. Semin Oncol. 2016; 43(6):682-689.","DOI":"10.1053\/j.seminoncol.2016.10.008"},{"key":"60674","doi-asserted-by":"crossref","unstructured":"Landgren O, Iskander K. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med. 2017; 281(4):365-382.","DOI":"10.1111\/joim.12590"},{"key":"60675","doi-asserted-by":"crossref","unstructured":"Schoen MW, Carson KR, Luo S, Sanfilippo KM. Outcomes in multiple myeloma based on comorbidities and race. Blood. 2019; 134(Suppl 1):383.","DOI":"10.1182\/blood-2019-121807"},{"key":"60676","doi-asserted-by":"crossref","unstructured":"Derman BA, Jasielec J, Langerman SS, Zhang W, Jakubowiak AJ, Chiu BCH. Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis. Blood Cancer J. 2020; 10(8):1-7.","DOI":"10.1038\/s41408-020-00347-6"},{"key":"60677","doi-asserted-by":"crossref","unstructured":"Merz LE, Story CM, Osei MA. Absolute neutrophil count by Duffy status among healthy Black and African American adults. Blood Adv. 2023; 7(3):317-320.","DOI":"10.1182\/bloodadvances.2022007679"},{"key":"60678","doi-asserted-by":"crossref","unstructured":"Van Alsten SC, Aversa JG, Santo L. Association between ABO and Duffy blood types and circulating chemokines and cytokines. Genes Immun. 2021; 22(3):161-171.","DOI":"10.1038\/s41435-021-00137-5"},{"key":"60679","doi-asserted-by":"crossref","unstructured":"Richardson PG, Jacobus SJ, Weller EA. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022; 387(2):132-147.","DOI":"10.1056\/NEJMoa2204925"},{"key":"60680","unstructured":"Hassoun H, Jacobus SJ, Voorhees PM. Response rates and outcomes in newly-diagnosed multiple myeloma (NDMM) patient subgroups receiving RVD\u00b1ASCT plus lenalidomide maintenance until progression in the phase 3 DETERMINATION trial. In Paris, France: 49th Annual Meeting of the European Society for Blood and Marrow Transplantation. 2023."},{"key":"60681","doi-asserted-by":"crossref","unstructured":"Niranjan SJ, Wenzel JA, Martin MY. Perceived institutional barriers among clinical and research professionals: minority participation in oncology clinical trials. JCO Oncol Pract. 2021; 17(5):e666-e675.","DOI":"10.1200\/OP.20.00970"},{"key":"60682","doi-asserted-by":"crossref","unstructured":"Kanapuru B, Fernandes LL, Fashoyin-Aje LA. Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials. Blood Adv. 2022; 6(6):1684-1691.","DOI":"10.1182\/bloodadvances.2021005482"},{"key":"60683","doi-asserted-by":"crossref","unstructured":"Sharrocks K, Spicer J, Camidge DR, Papa S. The impact of socioeconomic status on access to cancer clinical trials. Br J Cancer. 2014; 111(9):1684-1687.","DOI":"10.1038\/bjc.2014.108"},{"key":"60684","doi-asserted-by":"crossref","unstructured":"Oberle A, Brandt A, Voigtlaender M. Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA. Haematologica. 2017; 102(6):1105-1111.","DOI":"10.3324\/haematol.2016.161414"},{"key":"60685","doi-asserted-by":"crossref","unstructured":"Kaiser M, Hall A, Smith I. Extended intensified post-ASCT consolidation with daratumumab, bortezomib, lenalidomide and dexamethasone (Dara-VRd) for ultra-high risk (UHiR) newly diagnosed myeloma (NDMM) and primary plasma cell leukemia (pPCL): the UK Optimum\/Muknine Trial. Blood. 2022; 140(Suppl 1):1833-1835.","DOI":"10.1182\/blood-2022-159540"},{"key":"60686","doi-asserted-by":"crossref","unstructured":"Weisel K, Besemer B, Haenel M. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in patients with high-risk newly diagnosed multiple myeloma: planned interim analysis of the GMMG-Concept trial. Blood. 2022; 140(Suppl 1):1836-1838.","DOI":"10.1182\/blood-2022-156309"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283304\/76187","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283304\/76941","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11320\/76187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:08Z","timestamp":1794045908000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283304","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,26]]}}}